Skip to main content
. 2019 May 23;14(5):e0217131. doi: 10.1371/journal.pone.0217131

Fig 6. Antitumor effect of PKM2 inhibitor and shRNA-PKM2 in NSCLC s.c. tumor models.

Fig 6

(A) H358 tumors implanted mice were intratumorally treated with PKM2 inhibitor when tumors reached 5 mm in diameter. Tumor volume of each mouse was measured. Bars represent S.D. Each arrow indicated SMI injection to mice. On day 51, there was no significant difference between the groups. (B) Kaplan-Meier survival curves of H358 s.c. tumor-bearing mice after treatment were plotted. Overall sacrifice time (OST) was calculated based on the sacrifice of mice when tumors reached >2cm. Median survival: Control 64 days, 50μg/kg 142 days, and 500 μg/kg undefined. (C) H358 cells (non-silenced, mock-transfected, and PKM2-silenced) were implanted subcutaneously in nude mice and tumor volume was measured. Bars represent S.D. On day 100, there was significant difference between the groups; parental vs PKM2-silenced and mock-transfected vs PKM2-silenced (p = 0.0146 and 0.0112, respectively). (D) Kaplan-Meier survival curves of H358 s.c. tumor-bearing mice were plotted. Median survival: Non-silenced 102.5 days, mock-transfected 113.5 days, PKM2-silenced undefined.